Cipla Q1FY26 Earnings Results: Net Profit Rises 10% YoY to ₹1,298 Crore

Cipla Ltd reported consolidated Q1FY26 revenue of ₹6,957 crore, a 3.9% year-on-year increase. The India business (Rx, Generics, and Consumer Health) grew 6% YoY to ₹3,070 crore—crossing ₹3,000 crore for the first time in any Q1.

Cipla Q1FY26 Earnings: Strong Profit Growth and Margins

Net profit rose by 10.2% YoY to ₹1,298 crore, while EBITDA stood at ₹1,778 crore, maintaining a healthy margin of 25.6%. The company maintained operational efficiency despite supply chain challenges in the US.

Mixed Performance in Global Markets

• North America: Revenue dropped 7% YoY to ₹1,933 crore, despite new product launches like Nano Paclitaxel and Nilotinib Capsules.
• Africa: Sales rose 14% to ₹871 crore; South Africa saw 11% growth.
• Emerging Markets & Europe: Revenue climbed 11% YoY to ₹861 crore.
• API Business: Slight 3% growth to ₹102 crore.
• Others: Jumped 85% to ₹121 crore.

R&D and Financial Position

R&D spend was ₹432 crore (6.2% of sales). Cipla holds a strong net cash position of ₹10,379 crore. Total debt stands low at ₹459 crore, mainly from leases and working capital.

Balance Sheet Highlights (YoY Comparison)

• Equity rose to ₹32,665 Cr (from ₹28,058 crore)
• Inventory grew to ₹6,091 Cr
• Trade receivables increased to ₹6,254 crore
• Cash & equivalents rose to ₹10,838 crore

The MD & CEO highlighted Cipla's continued growth across geographies, strong consumer health performance, and a positive outlook for key brands and markets.

Read More: LIC Ties Up with Govt to Empower Rural Women via Bima Sakhi Yojana.

Cipla Share Price Movement

As of July 25, 2025, Cipla share price (NSE: CIPLA) was trading at ₹1,552.20, up 4.32% for the day. The stock has a market capitalisation of ₹1.25 lakh crore and a P/E ratio of 23.81. It offers a quarterly dividend of ₹3.26 per share. Cipla's 52-week high stands at ₹1,702.05, while the 52-week low is ₹1,335.00.

Conclusion

Cipla delivered a solid Q1FY26 performance with stable margins and double-digit profit growth. India sales were a major driver, and the company remains financially strong with healthy global momentum.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.